• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Uncategorized

Biolinq closes $100M Series C funding round for biosensor platform

April 22, 2025 By Jim Hammerand

A photo of Biolinq’s glucose sensor patch on a patient's upper forearm with a color-changing indicator light.

Biolinq said today it has closed a $100 million Series C funding round to advance its biosensor platform. “This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device,” Biolinq CEO Rich Yang said in a […]

Filed Under: Business/Financial News, Diabetes, Featured, Funding Roundup, Patient Monitoring, Uncategorized Tagged With: Alpha Wave Ventures, Aphelion Capital, AXA IM Alts, biolinq, biosensors, Diabetes, Hikma Ventures, LifeSci Venture Partners, M Ventures, RiverVest Venture Partners, Taisho Pharmaceutical, type 2 diabetes, wearable sensors, wearables

Lilly gets nod to market locally manufactured insulin in Egypt

December 17, 2024 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) announced today that the Egyptian Drug Authority approved insulin glargine manufactured in partnership with Eva Pharma. The companies launched their collaboration in 2022 to deliver a sustainable supply of high-quality, affordable human and analog insulin. It wants to bring insulin to at least 1 million people annually living with diabetes in low- to […]

Filed Under: Uncategorized Tagged With: Eli Lilly, Eva Pharma

Surmodics has positive data on multiple drug-coated balloons

November 16, 2023 By Sean Whooley

SurModics

Surmodics (Nasdaq:SRDX) today announced positive study results for two of its drug-coated balloon (DCB) technologies. The company presented data supporting the SurVeil and Sundance DCBs at the 50th Annual VEITH Symposium in New York. In the TRANSCEND trial, Surmodics evaluated the safety and efficacy of SurVeil versus the Medtronic In.Pact Admiral DCB. The trial evaluated […]

Filed Under: Uncategorized Tagged With: Surmodics

Embecta stock soars on first full-quarter results after BD spinoff

August 15, 2022 By Jim Hammerand

BD Diabetes Spinoff Embecta

Embecta (Nasdaq: EMBC) today posted third-quarter results today for the first time as a BD (NYSE: BDX) spinoff, beating the consensus forecast on Wall Street. The Parsippany, New Jersey-based diabetes technology company reported profits of $62.4 million, or $1.08 per share, on sales of $291.1 million for the three months ended June 30. RELATED: How […]

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Uncategorized, Wall Street Beat Tagged With: BD, Diabetes, embecta

Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review

August 11, 2022 By Jim Hammerand

A portrait of Better Therapeutics CEO and President Frank Karbe

Better Therapeutics (Nasdaq:BTTX) posted second-quarter quarter results today that beat the consensus forecast on Wall Street as it prepared to submit its first product for FDA review. Better Therapeutics has not yet generated revenue from the commercialization or sale of any product. The company went public through a special purpose acquisition company merger in October. […]

Filed Under: Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Technology, Uncategorized Tagged With: Better Therapeutics, Diabetes

Ariste Medical co-founder sees great potential for drug-coated implants and orthopedics

April 18, 2022 By Jim Hammerand

Orange polypropylene mesh coated with antibiotics

It’s been more than a decade since Lisa Jennings launched not one but two companies in the Great Recession. In 2020, she sold CirQuest Labs to MLM Medical Labs, where Jennings serves as chief scientific officer and managing director of U.S. operations. More recently, her pre-commercial medtech development startup, Ariste Medical, won FDA 510(k) approval for […]

Filed Under: Drug-Device Combinations, Featured, Grafts, Implants, Materials Testing, Orthopedics, Pharmaceuticals, Research & Development, Stents, Uncategorized Tagged With: Ariste Medical, implantable devices

Scancell picks PharmaJet’s needle-free injection systems to deliver COVID-19 vaccine candidates

September 14, 2021 By Sean Whooley

PharmaJet

PharmaJet announced today that its partner, Scancell, chose its needle-free injection platform to administer its COVID-19 vaccine candidates. Scancell selected Golden, Colorado-based PharmaJet’s devices to administer two SARS-CoV-2 DNA-based vaccine candidates, SCOV1 and SCOV2. The vaccines will be exclusively administered using the PharmaJet Tropis and PharmaJet Stratis needle-free injection systems. According to a news release, […]

Filed Under: Uncategorized Tagged With: coronavirus, COVID-19, PharmaJet, Scancell

Insulet sues Roche over diabetes tech patent

May 12, 2021 By Nancy Crotti

Insulet Roche

Insulet (NSDQ:PODD) is suing Roche Diabetes Care in the U.K., claiming that Roche prematurely began selling tubeless insulin pumps covered by an Insulet patent three years before that patent expires. The trial for the lawsuit, filed in August 2020, began this week in the U.K. High Court. Insulet claims that Roche has been infringing the […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Uncategorized

Qosina offering SmartSite swabbable needle-free injection sites

November 3, 2020 By Chris Newmarker

Qosina SmartSite swabbable needle-free injection sites

Qosina (Ronkonkoma, N.Y.) is touting the variety of SmartSite swabbable needle-free injection sites that it offers. The needle-free injection sites feature an ergonomic design and a smooth, flat top that can be easily disinfected, according to Qosina. Said the company: ” These components are equipped with a valve, that when activated, forms an airtight seal […]

Filed Under: Uncategorized Tagged With: Qosina

Abbott, Tandem seal deal to combine CGM, insulin delivery tech

June 29, 2020 By Nancy Crotti

Abbott logo updated

Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott’s Freestyle Libre CGM with Tandem’s t:slim X2 pump to monitor glucose without fingersticks. The agreement covers the technical development of device integration […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Featured, Uncategorized, Wall Street Beat Tagged With: abbott, Tandem Diabetes Care

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS